🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of rising global incidence, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US FDA in mid-December for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This approval represents a major breakthrough in the therapy of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Data and Global Access

As per data published in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This establishes an similar efficacy with the current standard treatment, which involves an injection and a pill. The research enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have shared optimism. The availability of a easy-to-administer therapy of this kind is described as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.